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Abstract
Parkinson’s disease (PD) has had six genome-wide association studies (GWAS) conducted as well as several gene expression
studies. However, only variants in MAPT and SNCA have been consistently replicated. To improve the utility of these
approaches, we applied pathway analyses integrating both GWAS and gene expression. The top 5000 SNPs (p,0.01) from a
joint analysis of three existing PD GWAS were identified and each assigned to a gene. For gene expression, rather than the
traditional comparison of one anatomical region between sets of patients and controls, we identified differentially
expressed genes between adjacent Braak regions in each individual and adjusted using average control expression profiles.
Over-represented pathways were calculated using a hyper-geometric statistical comparison. An integrated, systems meta-
analysis of the over-represented pathways combined the expression and GWAS results using a Fisher’s combined
probability test. Four of the top seven pathways from each approach were identical. The top three pathways in the meta-
analysis, with their corrected p-values, were axonal guidance (p=2.8E-07), focal adhesion (p=7.7E-06) and calcium signaling
(p=2.9E-05). These results support that a systems biology (pathway) approach will provide additional insight into the
genetic etiology of PD and that these pathways have both biological and statistical support to be important in PD.
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Introduction
Parkinson’s disease [PD (OMIM 168600)] is a complex
neurodegenerative disease thought to be due to interactions
between genetic susceptibility and environmental stressors. Several
genome-wide association studies (GWAS) on PD have been
performed recently [1–5], but only two genes have demonstrated
statistical significance and replication across data sets: the
Microtubule-Associated Protein Tau (MAPT) and a-synuclein
(SNCA). However, many genes have been replicated in these
datasets, but after correcting for multiple testing, have not reached
genome-wide significance. Thus, additional approaches are
needed to maximize the existing genetic data to identify genes
and pathways important in developing PD.
A criticism of many of the current GWAS analytical approaches
is that they focus primarily on the most significant SNPs occurring
in an analysis [6], and that this may not incorporate known
biological information that could increase their value. One way to
utilize biological information is a pathway-analysis approach,
based on the realization that complex diseases are likely affected
by many genes contributing in a common pathway [2,7–10].
Another source of genetic data for research in complex genetic
disease has been gene expression [11–13]. But interpretation of
these gene expression results, especially in complex diseases, has
potential difficulties. For one, disease risk may well be conferred
through means other than gene expression changes, and thus
genetic variation important to disease risk may not affect gene
expression directly, and not be detected through such studies.
Another often cited criticism is that many of the differentially
expressed genes between patients and controls may actually be
secondary to degenerative changes in patients, and thus have little
contribution to the actual disease process.
The classical experimental method employed in gene expres-
sion analyses has been to analyze a group of disease cases versus a
group of controls. One flaw of this design is that individual sample
variations that are secondary to sample handling, agonal state and
other general factors can mask or introduce error in the analysis,
as the model lacks an internal reference for these effects on gene
expression. Further, individuals inlate-onset disorderslikePD will
likely be at different stages of neurodegeneration at death, and
thus pooling different brain regions that may be differentially
affected from these individuals will introduce more error in the
analyses.
We hypothesize that by combining a pathway approach for
both GWAS and gene expression we can address many of these
concerns and identify those pathways important in the pathogen-
esis of PD. To reduce error in gene expression, we identified
differentially expressed genes between different brain tissues
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16917involved in PD in a single individual, rather than comparing
average gene expression results from the same anatomical tissue in
groups of cases and controls. We then used these data to identify
pathways, which were significantly over-represented by differen-
tially expressed genes. Further, a pathway analysis was performed
to identify pathways over-represented in the GWAS data.
Convincingly, out of 205 potential human pathways listed in the
Kyoto Encyclopedia of Genes and Genomes (KEGG), four of the
top seven most significant pathways from each approach were
identical and meta-analysis demonstrated 10 pathways to be
highly significant. These shared pathways from both gene
expression and GWAS therefore have both biological and genetic
support for their importance in the pathogenesis of PD.
Results
Gene Expression Analysis
Both control and patient subtractions gave a large number of
differentially expressed genes between different tissue regions. In
controls, this represents the normal functional variation between
brain regions. Thus, the average control values were subtracted
from each patient sample, normalizing the subtraction results.
After the subtraction of the control ratios, a large number of genes
remained differentially expressed between subtraction pairs. These
were used in the subsequent pathway analysis. 6759 genes are
differentially expressed and 42 over-represented pathways were
identified (significance level: p#0.05) (Figure 1).
Figure 1. The Venn diagram shows 25 and 42 over-represented pathways in the GWAS (green) and the expression PD (pink) studies
respectively. Twelve over-represented pathways common to both PD studies are also shown (yellow). The pathway’s rank in the meta-analysis is
provided in parenthesis.
doi:10.1371/journal.pone.0016917.g001
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Twenty-five over-represented pathways at significance level
p#0.05 (Figure 1) were seen in the 5000 SNPs. The 10 most
statistically significant over-represented pathways are shown in
Table 1. A total of 12 over-represented pathways are common to
both the GWAS and the gene expression PD studies (Figure 1).
The list of over-represented pathways common for the two PD
studies (GWAS or gene expression) does not change if the gene
expression data are considered as two sub groups (up–regulated
and down-regulated) or merged into a single group (of differen-
tially expressed genes). Additionally, four of the top seven over-
represented pathways from each approach (Table 1) were
identical; these are: calcium signaling, axon guidance, focal
adhesion and adherens junction.
Meta-Analysis of Over-represented Pathways in PD
A meta-analysis of over-represented pathways was developed
and performed to identify statistical significance in the combined
GWAS and gene expression PD study. For the gene expression
data, the up–regulated and down-regulated genes are merged into
a single class of differentially expressed genes. The top 20 over-
represented pathways from the meta-analyses of over-represented
pathways are shown in Table 2.
Discussion
The pathways identified by integrating GWAS and gene
expression data reported here have both statistical and biological
support to be involved in PD. This further suggests that many of
the changes seen in gene expression studies are not due to
secondary, non-specific changes, but rather have direct influence
on the pathogenesis of the disease. It also demonstrates that the
pathways derived from the GWAS have biological support. The
convergence of these two greatly reduces the risk that these
pathways are biased by size of the significant gene, with larger
genes having greater chance of having a significant SNP [14].
O’Dushlaine [15] examined the effect of the number of genes in a
pathway towards significance, but didn’t see any correlation.
Supporting this are recent studies of pathway analyses in other
disorders such as Diabetes and Inflammatory diseases [14,16],
where little overlap was seen between these pathways and those
reported here. Had the size of the pathway been a prominent
factor, more overlap would be expected. Elbers et al. [14]
examined this possibility as well, but only found it to be a problem
with two of the pathway classification tools they tested, neither
which was utilized in this analysis.
Previously, a SNP ratio test (SRT) has been developed to assess
enrichment of significant associations from GWAS in context of
KEGG pathways [15]. One difference between the SRT method
[15] and the method described here is with respect to the mapping
of SNPs to genes. In our study, the mappings of SNPs to genes are
obtained using a window of 20 Kbp on either side of the SNP. The
genes identified within the window are added to the gene list of
interest. Using the criterion, if no gene was identified for the SNP
in question then the two neighboring genes, irrespective of
distance separation between the SNP and gene, are added to the
gene list of interest. In the O’Dushlaine et al. study [15], the
mappings of SNPs to genes are obtained by parsing the db SNP
Table 1. The top ten over-represented pathways from (a) the
GWAS PD study and (b) the gene expression PD study.
(a) GWAS P value
Melanogenesis 6.51E-05
Axon guidance 8.05E-05
Cell adhesion molecules (CAMs) 9.62E-05
Neuroactive ligand-receptor interaction 3.70E-04
Adherens junction 6.95E-04
Focal Adhesion 8.56E-04
Calcium Signalling pathway 1.94E-03
Pentose and glucuronate interconversions 7.06E-03
Starch and sucrose metabolism 7.90E-03
Drug metabolism - cytochrome P450 8.11E-03
(b) Gene expression
Axon guidance 7.00E-07
Focal adhesion 2.11E-06
Calcium signaling pathway 3.70E-06
Renal cell carcinoma 9.18E-06
Regulation of actin cytoskeleton 2.24E-05
Adherens junction 9.64E-05
ErbB signaling pathway 1.03E-04
Type I diabetes mellitus 1.13E-04
Long-term potentiation 4.37E-04
Non-small cell lung cancer 4.84E-04
The pathways are presented in the decreasing order of significance.
doi:10.1371/journal.pone.0016917.t001
Table 2. The top twenty over-represented pathways
determined by the meta-analysis combining the GWAS and
the gene expression PD studies.
GWAS and Gene Expression Meta_P-value
Corrected
P-values
Axon guidance 1.39E-09 2.79E-07
Focal adhesion 3.82E-08 7.68E-06
Calcium signaling pathway 1.42E-07 2.85E-05
Cell adhesion molecules (CAMs) 1.04E-06 2.09E-04
Adherens junction 1.18E-06 2.37E-04
Renal cell carcinoma 2.70E-06 5.43E-04
Regulation of actin cytoskeleton 1.35E-05 2.71E-03
Non-small cell lung cancer 8.40E-05 1.69E-02
Melanogenesis 9.59E-05 1.93E-02
ErbB signaling pathway 1.15E-04 2.31E-02
Long-term potentiation 2.62E-04 5.27E-02
Glioma 2.71E-04 5.44E-02
Type I diabetes mellitus 3.53E-04 7.10E-02
Pancreatic cancer 6.28E-04 1.26E-01
Phosphatidylinositol signaling system 6.98E-04 1.40E-01
Neuroactive ligand-receptor interaction 1.31E-03 2.63E-01
Complement and coagulation cascades 1.39E-03 2.79E-01
Heparan sulfate biosynthesis 1.62E-03 3.25E-01
MAPK signaling pathway 1.71E-03 3.43E-01
Endometrial cancer 2.86E-03 5.75E-01
The over-represented pathways are presented in rank order.
doi:10.1371/journal.pone.0016917.t002
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than 2 Kbp from the 59 of the gene and less than 0.5 Kbp 39 from
the end of the gene.
One reason we chose our method was that variants regulating
transcript expression or transcriptional control are likely to be
important in complex disease, and to date many associated SNPs
in these disorders have been located in ‘‘gene deserts’’ or non-
coding regions. While there have been no systematic studies to
investigate the affect of upstream and downstream analysis for
the cause and the effect of genetic variation, one study has shown
that 95% of genetic variation affecting transcript levels is within
2 0K b po ft h et r a n s c r i p ts t a r ta n de n ds i t e s[ 1 7 ]a n dt h e r e f o r e
provides support for our use of 20 Kbp radii for mapping SNPs
to genes. Furthermore, it is likely that SNPs located in gene
deserts may coincide with enhancers and silencers, thereby
providing a rationale to search beyond the 20 Kbp to attach a
SNP to gene when protein coding genes are absent within the
initial 20 Kbp search. Studies using conserved non-coding
elements (CNEs) and in-vivo GFP enhancer assays have shown
that the majority of CNEs are located in gene deserts and are
likely to up-regulate effector genes of up to 250 Kbp away. Many
of the CNEs have a larger distance of separation from the target
genes (.1 Mbp) [18–22]. Targets for these enhancers are
enriched for the regulation of transcriptional control or
developmental genes [19,20], many of which have been
identified in these pathways. It is likely the methods used here
to map SNPs to genes will be valuable to establish evolutionary
significance of long range cis-regulation and trans-regulation in
complex diseases [17,20,22–26].
We believe that the measurement of gene expression compared
between different CNS regions affected by PD within the same
person helps adjust for factors such as agonal state, postmortem
interval and other environmental effects that affect RNA quality.
By using differences between anatomical regions from the same
patient, we create an internal reference for these effects. Further,
this methodology should be more sensitive to identifying
expression changes in individuals at different stages of disease
that would be ‘‘washed out’’ by the traditional analysis of groups of
cases versus controls.
In this study, we used Fisher’s combined probability test to
combine the results of pathway analysis in a large GWAS dataset
and a smaller expression dataset. One limitation of this approach
is that it gives equal weight to the results from each dataset. While
this does not seem to be a big concern in the current study given
the concordant results in the two datasets, it may not be optimal
for other studies attempting to follow a similar approach with
more disparate results (and heterogeneous independent data sets).
In such cases, weighting each dataset’s contribution by a quality
score, effect size, or variance on the test statistic might be desirable
and can be accomplished by employing more complex methods
that accommodate such weights.
Both melanoma and melanogenesis pathways were identified in
the GWAS data as significant pathways (Figure 1), and the
melanogenesis pathway was ranked ninth in the meta-analysis
(corrected p-value =1.9E-02). This seems biologically intuitive, as
melanin, tyrosine and their biosynthesis (Figure 2) are tightly tied
to the production of dopamine, the neurotransmitter deficient in
PD. Interestingly, other investigators have suggested that common
genetic determinants exist in the causal pathway to melanoma and
PD [27–29]. It seems also intuitive that much of this pathway is
lost in the gene expression analyses due to the destruction of
substantia nigra, and therefore is not prominent in the gene
expression results, though several genes in the pathway are found
significant in the expression analysis.
What is striking is that none of the SNPs in the melanogenesis
pathway (Figure 2) have been strongly implicated in current
association studies. This is because no one SNP or gene in these
pathways has met the stringent criteria of genome-wide statistical
significance despite multiple GWAS studies. The idea of focusing
on single gene or SNP effects when examining a disease is derived
from the very successful research over the past 30 years on
Mendelian (single gene) disorders. But, as seen here, the origin of
complex disease is really that of the cumulative effect on genes
functioning together in pathways. The data reported here support
the thoughts of other authors that pathway analysis is the more
appropriate analysis when looking for genes involved in these
diseases [6]. We would suggest that pathway analysis becomes part
of every approach to gene discovery in complex disease. It seems
likely, based on the concordance seen here by the three GWAS
studies in Edwards et al. [1] and the gene expression data, that
pathway analyses are more likely to replicate across GWAS studies
than single gene analyses.
It is interesting that the other well known Mendelian PD genes
(SCNA, PARKIN, DJ1, and PINK1) are not directly included in
any of the identified significant pathways. There are several
potential reasons for this finding. It may reflect the lack of
knowledge about the regular function of these genes. Or it is
possible that Mendelian mutations leading to PD are unique
genetic initiation points for PD, and while very insightful to the
general mechanisms that can lead to PD, are not involved in
directly in the pathways whose genetic variability contribute to
susceptibility to ‘‘idiopathic’’ PD.
Axon guidance was one of the top over-represented pathways,
and is important for brain development, dopaminergic axonal
maintenance, regeneration and target recognition. In 2005,
Maraganore et al. [30] published a tiered association study on
PD and identified a SNP in semaphoring 5A (SEMA5A) as the
most significant association. While this has not been replicated in
subsequent studies, as SEMA5A is important in axon guidance,
they examined SNPs in other genes in this pathway to attempt to
utilize these SNPs to predict outcome in patients. They found
support for additional axonal guidance pathway genes to be
associated with PD, and using the dataset from Papapetropoulos
et al. [11] found more differential expression than they expected for
45 genes in the axonal guidance pathway, using only data from the
substantia nigra and striatum. Wang et al. [31] using a different,
smaller GWAS dataset, also found it to be the only significant
pathway. Sutherland et al. [32] did a meta-analysis of reports of
gene expression studies in PD, excluding the data utilized here,
and also found axon guidance to be one of the major pathways
over-represented, as did Bossers et al. in a recent gene expression
study [33].
Focal adhesions (FA) are specialized regions where the cell
interacts with the extra cellular matrix (ECM). One primary
function of FA is linking the actin cytoskeletal network to the
transmembrane integrins (KEGG). Other FA are involved in
signaling between the cell and the ECM, as well as helping
regulate phosphorylation of molecules like MAPT, and influencing
receptors for growth factors. Errors in the interaction between the
ECM/FA can lead to a form of apoptosis called anoikis [34].
Caltagarone et al. [35] has suggested that errors in the FA/integrin
signaling pathway, in response to oxidative stress and fibillary Ab,
is one of the key pathways in inducing cell death in Alzheimer
disease (AD).
Adherens Junction (AJ) proteins are involved in the cell-cell
adhesions. In tissues such as skin, they are involved in maintaining
cell contact during external stress such as movement [36].
Cadherins are core AJ proteins and interact with microtubules
Pathways in Parkinson’s Disease
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maintaining the blood-brain barrier (BBB). Interestingly, one of
the primary regulators of AJ in the BBB is calcium [37]. Changes
in BBB have been reported in normal aging [38], and several
studies have suggested changes in BBB exist in PD patients
[39,40].
The calcium signaling pathway (Figure 3) has an important role
in regulating a great variety of neuronal processes, as mentioned
above. Its high rank in the meta-analysis fits well with the recent
work that has shown the SNGRA dopamine neurons have an
unusual reliance on voltage-dependent L-type Ca2+ channels in
autonomous pace-making. This suggests that the mitochondrial
stress created by sustained Ca2+ entry could be responsible for
their selective vulnerability, rather than simply a late stage
consequence [41,42]. This hypothesis is also consistent with the
centrality of mitochondria in prevailing models of pathogenesis in
PD, as it serves as one of the primary sources of Ca++ buffering.
Deficiency of one known PD gene, PINK1, has been reported to
cause mitochondrial accumulation of calcium, resulting in
mitochondrial calcium overload [43].
Recently, Satake et al. [44] reported an association reaching
genome-wide significance of BST1 with PD in a Japanese
population. Interestingly, BST1 (CD157) is closely related to
CD38, which is one of the genes in the calcium pathway, and did
demonstrate significance in our GWAS data as well (Figure 3).
These two ectoenzymes and surface receptors utilize NAD+ and
are located within 50 kb of each other on 4p15. It is possible that a
common variation affecting both genes is in linkage disequilibrium
with the different SNPs in each population.
The mitogen-activated protein kinases (MAPKs) are a major set
of metabolic reactions and thus it is not too surprising they appear
to play a central role in biological cross-talk of the various
identified pathways (Figures 4 & 5). MAPKs are serine-threonine
kinases that mediate intracellular signaling associated with a host
Figure 2. KEGG pathway for melanogenesis. Similar to a gene expression array, those significant genes in the GWAS study are green, those in
the expression study are pink and those that are significant in both are yellow.
doi:10.1371/journal.pone.0016917.g002
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survival, death and transformation [45]. Mammals express at least
four distinctly regulated groups of MAPKs: the extracellular
signal-related kinases (ERK)-1/2, c-Jun N-terminal kinases
(JNK1/2/3), p38 proteins (p38 alpha/beta/gamma/delta) and
ERK5. The MAPT gene (tau) is one of the most replicated
associations with risk for PD, and is in the MAPK pathway which
is activated by ERK (MAPK1). Both JNK and ERK have been
shown to contribute directly to mitochondrial dysfunction by
suppressing oxidative respiration when activated by various
models of PD [46]. Parkin has been reported to directly inhibit
JNK activation via ubiquitination of JNK pathway mediators [47].
While PD is one of the most common movement disorders, the
molecular mechanisms underlying neuronal degeneration in PD
are still unclear [48]. By converging independent genomic
datasets, we have identified pathways that have both biological
function and genetic support to be important in PD. As pathways,
they should be more replicable between datasets than single SNPs.
Our data strongly supports the concept that complex diseases
should be evaluated as pathway diseases and that the failure of
GWAS studies to identify and replicate significant SNPs may
reflect the conceptual failure of the genetics field to move beyond
single-SNP analytic strategies.
Most of the pathways identified here have not been extensively
studied in PD to date. It is interesting that the pathways from the
meta-analysis suggest that it is the genes involved in the cells
signaling and structural interactions with its environment whose
genetic variation seems to have the most effect on susceptibility to
PD. While it could be argued that the identification of these
pathways are secondary changes due to cell loss, the convergence
of the GWAS data on the same pathways argues strongly against
this. This seems to lead one in a different direction than much of
the current PD research based on specific single gene mutations.
These pathways are important to how the cells react to stress and
one another, and are also important in developmental aspects of
the CNS as well. They raise the interesting concept that perhaps
all of us are exposed to the initiating events or stresses that give rise
to PD, and it is the cumulative genetic makeup of these and other
similar pathways in each individual that strongly contributes to
whether we develop PD or not.
Materials and Methods
Gene Expression Samples
For the gene expression analysis, we utilized the Affymetrix Plus
2.0 microarray data set of Papapetropoulos et al. [11]. In this study,
22 PD patients and 23 controls were collected through the
University of Miami Brain Bank (D. C. Mash, Director). Twenty-
one different brain regions from each individual were isolated and
gene expression was performed. All patients met UK PD Society
Brain Bank diagnostic criteria and controls were clinically normal
and had no evidence of neurodegeneration upon autopsy. The
average age of controls was 78 years; PD cases were 74 years. The
six anatomical regions used by Braak et al to determine their
neuropathic stages of PD [49] provide a convenient method for
identifying multiple anatomical regions of the brain involved in the
Figure 3. KEGG pathway for calcium signaling. Similar to a gene expression array, those genes with significant expression in the GWAS study
are green, those in the expression study are pink and those that are significant in both are yellow.
doi:10.1371/journal.pone.0016917.g003
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all patients to have the same anatomical regions available for the
analysis. But Papapetropoulos et al. did not perform gene
expression analysis on many of the 21 anatomical brain regions
isolated per person due to poor quality mRNA of those specific
tissues. Thus, we sorted the raw gene expression data per patient
per brain region to maximize the availability of samples for our
analysis. No individuals had gene expression data available on
tissue lying in all six "Braak" regions. Seven patients and four
controls had gene expression data on five of the six anatomical
regions and these were used for the analysis. The five brain regions
representing the Braak stages were: the dorsal IX/X motor
nucleus (DMV) for Stage 1, locus ceruleus (LCER) for Stage 2,
substantia nigra (SNGRA) for Stage 3, putamen (PTMN) for Stage
4, and the insula (INSLA) for Stage 5. The general outline of the
methodology is shown in Figure 6. As shown, the differential
expression was measured between anatomically adjacent tissues
within the same individual first. Thus, subtraction LCER vs.
DMV was calculated by taking the expression value of each gene
in DMV and subtracting it from the expression value in LCER.
The process was repeated for each stage, ending up with four
subtractions per individual: LCER vs. DMV, SNGRA vs. LCER,
PTMN vs. SNGRA, and INSLA vs. PTMN.
Gene Expression Analysis
The raw data were normalized using the GCRMA algorithm in
GeneSpring (Agilent Technologies, Santa Barbara, CA). Statistical
tests, fold change calculations, hierarchical clustering of the data,
and annotations were all performed in GeneSpring GX7.3.1. The
data were then imported to Excel for further manipulations.
For each patient or control individual, genes that were
significantly differentially expressed with a Benjamini q-value
of ,0.05 [50] were then taken into a subtraction analysis. Ratios
were then selected at each stage with respect to the stage previous
to it. Thus, subtraction LCER vs. DMV was calculated by taking
t h ee x p r e s s i o nv a l u eo fe a c hg e n ei nD M Va n ds u b t r a c t i n gi t
from the expression value in LCER. The subtractions were
performed using data manipulation tools in Excel. The process
was repeated for each stage, ending up with four subtractions:
LCER vs. DMV, SNGRA vs. LCER, PTMN vs. SNGRA, and
INSLA vs. PTMN. The four controls were treated as replicates
and the average expression profile for each subtraction of the
control data was calculated. This analysis was done to allow us to
discount the control expression profiles from the patient data,
without making any assumptions as to which controls would be
matched to which patients. The average control expression
profile per brain region was then subtracted from the corre-
Figure 4. KEGG pathway for MAPK. Similar to a gene expression array, those genes that are significant in the GWAS study are green, those in the
expression study are pink and those that are significant in both are yellow.
doi:10.1371/journal.pone.0016917.g004
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(Figure 6). Statistically-determined differentially expressed genes
(Benjamini p-value of ,0.05) at each transitional stage were
selected for further analysis. Within each subtraction, genes of
values (fold change differential) $1.6 are considered to have been
up regulated between the two brain regions. Similarly, if the
Figure 5. Cross-talk amongst over-represented pathways in PD. The links are defined by the LinkDB function from the KEGG website. The top
ten over-represented pathways from the GWAS and expression studies (Table 1) plus the top twenty over-represented pathways from the meta-
analysis (Table 2) are shown. The insulin signaling pathway, linking the MAPK signaling with the starch and sucrose metabolism, is also shown. Three
pathways (drug metabolism - cytochrome P450, heparan sulfate biosynthesis and type 1 diabetes mellitus shown with gray thatched background)
did not cross talk with the other top pathways over-represented in this study. The pathway’s rank in the meta-analysis is provided in parenthesis. The
pathways unique to the GWAS PD study are green, those unique to the expression PD study are pink and the pathways common to both expression
and GWAS PD studies are yellow.
doi:10.1371/journal.pone.0016917.g005
Pathways in Parkinson’s Disease
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the later Braak stage than in the earlier Braak stage. Note that
since there is no replication per se, each individual is unique and
each brain region is unique per individual, using standard t-tests
or one-way ANOVAs for comparison of gene expression is not
applicable to this data set. The lists of differentially expressed
Figure 6. Conversion of Gene Expression and GWAS Pathways. For gene expression analysis, differentially expressed genes between
adjacent tissues affected in PD were identified in each individual and adjusted using average control expression profiles. Three subtractions were
used to identify genes of interest in PD. The first subtraction between two adjacent tissues relates to a given PD patient (eg CASE N). The second
subtraction is in controls, where a similar subtraction as above is performed, and then averaged over the four controls for the two given adjacent
tissues. This is denoted as CONTROLAVG. To establish if gene X is of interest in PD between two adjacent tissues, the CONTROLAVG was subtracted
from the first subtraction for each patient. An overview of the GWAS PD study is shown. Pathway analysis was performed on each of the GWAS and
gene expression PD gene sets derived. Two types of convergence were performed. First, significantly over represented pathways common in both
studies were identified (Figure 1). Second, a meta-analysis was carried out to combine the results obtained from the gene expression and the GWAS
PD pathway analyses (Table 2). DMV=dorsal motor nucleus, LCER= locus ceruleus, SNGRA= substantia nigra, PTMN= putamen, INSLA= insula.
doi:10.1371/journal.pone.0016917.g006
Pathways in Parkinson’s Disease
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analysis.
GWAS sample Analysis: Mapping SNPs to genes
We used data from a previous study [1], which is a joint analysis
of three PD GWAS datasets imputed up to the Illumina 610
genotyping chip (1752 PD cases and 1745 controls). To focus on
the most significant pathways, 5,000 SNPs with the most
significant association (p,0.01) were used in this analysis. To
map SNPs to genes, we used the chromosome and position of the
SNP, and located the genes within a window 20 Kbp upstream
and downstream of the SNP. The annotations for mapping the
SNPs to the genes were from dbSNP version 129 and the
ENSEMBL database (homo_sapiens_variation_50_361; homo_
sapiens_core_50_361; homo_sapiens_registry_50_361) [51]. The
annotations for human genome assembly version 36.1 were used.
If these top SNPs contained multiple SNPs for the same gene, the
gene was only counted once, so linkage disequilibrium would not
be a factor. If there were no genes found in a+/220 Kbp window,
the closest gene on each side of the SNP were both included. A
PERL script (snps2Genes.pl) was developed and used to perform
the above analysis. A query list (comprising 2619 genes) for
pathway analysis was derived from the top 5000 SNPs. The
reference gene list was obtained from the joint analysis dataset [1]
with combined sample generated genotypes at 495,715 SNPs after
imputation (and sample SNP quality control filters). These SNPs
were used as the reference data set and the SNP to gene mapping
protocol was used to map SNPs to genes; 18,810 unique genes
were established as the reference gene list. Only protein coding
genes were considered for the query and reference.
Pathway Analysis
GOstats [52], a Bioconductor package written in R, was used to
examine the pathways in KEGG [53–55]. The org.HS.eg.db
package was used to assign KEGG pathway annotations to Entrez
gene identifiers. Over-represented pathways for given gene lists
were calculated using a classical hyper-geometric statistical
comparison of a query gene list against a reference gene list using
GOstats. The GOstats method was applied to the expression and
the GWAS data independently. For the pathway analysis of
expression data, the query gene lists are the differentially expressed
genes. The differentially expressed genes were used to compare
against a reference set of 21,218 genes on the microarray chip used
in Papapetropoulos et al. (hgu133plus2). Up-regulated genes were
considered separately from down regulated genes unless otherwise
stated. For the pathway analysis of GWAS data, the query gene list
was derived from SNPs with p-values #0.01, (5000 SNPs) and the
reference gene list was obtained from the GWAS (see previous
section). A PERL script (genes2ORPathways.pl) was developed
and used to search for over-represented pathways in query gene
lists relative to the reference gene lists. While there are 343
pathways currently in KEGG pathway database only 205 were
relevant to the human genome [55].
Meta-analysis of over-represented pathways
A meta-analysis of the pathway results from GOstats was
performed using the Fisher’s combined probability test. As the
method requires independent tests, we did the meta-analysis on
the GWAS pathway analysis and a pathway analysis based on a
gene list of differentially expressed genes. P-values are combined
by adding the -2ln (p-value) for the two tests for a pathway. This
value follows a chi-square distribution which was used to
determine the combined p-value.
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